Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.5400
-0.0326 (-5.69%)
At close: Jun 12, 2026, 4:00 PM EDT
0.5611
+0.0211 (3.91%)
After-hours: Jun 12, 2026, 7:12 PM EDT
Citius Pharmaceuticals Employees
Citius Pharmaceuticals had 23 employees as of September 30, 2025. The number of employees did not change compared to the previous year.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$243,974
Profits / Employee
-$2,008,743
Market Cap
14.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 23 | 0 | - |
| Sep 30, 2024 | 23 | 1 | 4.55% |
| Sep 30, 2023 | 22 | 1 | 4.76% |
| Sep 30, 2022 | 21 | 6 | 40.00% |
| Sep 30, 2021 | 15 | 5 | 50.00% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Sensei Biotherapeutics | 29 |
| Curis | 24 |
| OSR Holdings | 22 |
| Moleculin Biotech | 17 |
| Lexaria Bioscience | 7 |
| Akari Therapeutics, | 6 |
| GT Biopharma | 1 |
CTXR News
- 13 days ago - Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO - TheFly
- 13 days ago - Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - PRNewsWire
- 19 days ago - Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PRNewsWire
- 22 days ago - Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders - TheFly
- 23 days ago - Citius Pharmaceuticals Registration statement: Registration filing - Filings
- 27 days ago - Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright - TheFly
- 4 weeks ago - Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PRNewsWire
- 4 weeks ago - Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PRNewsWire